相关实验视频

Updated: Jun 5, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

发现VU0467319:一个M₁正的体调节器候选者,进入临床试验

Michael S Poslunsey^1,2, Michael R Wood^1,2, Changho Han^1,2

¹Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.

ACS chemical neuroscience

|December 11, 2024

概括

VU0467319 (VU319) 是一种新型的M1阳性体调节器 (PAM),已成功完成I期试验. 它准了中央M1肌肉蛋白受体,而不会引起不良的胆固醇效应,对认知障碍有希望.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

M1肌受体是认知增强的关键目标.
开发具有最小副作用的选择性M1正调节器 (PAM) 是一个挑战.
胆固醇副作用限制了之前的中枢神经系统药物开发.

研究的目的:

为了披露VU0467319 (VU319),一个新的M1 PAM.
报告VU319的第一阶段单次上升剂量 (SAD) 临床试验成功完成.
评估VU319的安全性,耐受性和目标接触.

主要方法:

VU319的特征是M1 PAM具有高的中枢神经系统透率和有利的药理动力学.
临床前研究评估了认知模型中的疗效和老鼠,狗和非人类灵长类动物的安全性.
在健康志愿者中进行了第一阶段SAD临床试验 (NCT03220295).

主要成果:

VU319表现出中度M1 PAM强度与最小的M1激动性.
临床前毒理学和第一阶段SAD试验表明缺乏胆固醇不良反应.
在第一阶段试验中,在最高剂量时观察到目标参与信号.
VU319表现出高度的中枢神经系统 (CNS) 透和有利的多种类型的药理动力学.

结论:

VU319是第一个成功完成第I阶段SAD试验的M1 PAM.
VU319显示在选择性向中央M1肌素受体的可行性,没有胆固醇副作用.
VU319代表了治疗认知功能障碍的有前途的临床候选人.

关键词:

认知认知认知代谢代谢代谢代谢肌肉酸乙胆受体亚型1 (M1) 的肌肉酸乙胆受体积极的全调节器 (PAM)

更多相关视频

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...